LA FONDAZIONE

PUBBLICAZIONI SCIENTIFICHE

IMPACT FACTOR

L'impact factor dei lavori scientifici è attualmente di 1648.78 punti considerando l'I.F. più recente della rivista


I risultati delle ricerche finanziate dalla Associazione in questi anni sono stati presentati in numerosi convegni e congressi nazionali ed internazionali e pubblicati su importanti riviste scientifiche.
  • Rivista:
  • Frontieres in Oncology-Breast Cancer (ISSN ), 2021

137 – Obesity in postmenopausal breast cancer patients: it is time to improve actions for a healthier lifestyle

  • AUTORI: Cortesi L., Galli G.R., Domati F., Conte L., Manca L., Berio M.A., Toss A., Iannone A., Federico M.
  • Rivista:
  • Journal of Clinical Oncology (ISSN 0732-183X), 2021

136 – Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma: the FOLL12 study

  • AUTORI: Luminari S., Manni M., Galimberti S., Versari A., Tucci A., Boccomini C., Farina L., Olivieri J., Marcheselli L., Guerra L., Ferrero S., Arcaini L., Cavallo F., Kovalchuk S., Skrypets T., Del Giudice I., Chauvie S., Patti C., Stelitano C., Ricci F., Pinto
  • Rivista:
  • Journal of Perzonalized Medicine 11:6-580, 2021 - I.F. 4,94

135 – Clinical and pathological features of breast cancer in systemic sclerosis: results from Sclero-Breast Study

  • AUTORI: Toss.A., Spinella A., Isca C., Vacchi C., Ficarra G., Fabbiani L., Iannone A. et al.
Abstract: The most common breast cancer (BC) susceptibility genes beyond BRCA1/2 are ATM and CHEK2. For the purpose of exploring the clinicopathologic characteristics of
  • Rivista:
  • Blood Advances 5:3-640:648, 2021 - I.F.6,68

134 – ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project

  • AUTORI: Shoustov A., Cabrera M.E., Civallero M., Bellei M., Ko Y.H., Manni M., Skrypets T. et al.
Abstract: The most common breast cancer (BC) susceptibility genes beyond BRCA1/2 are ATM and CHEK2. For the purpose of exploring the clinicopathologic characteristics of
  • Rivista:
  • Genes 12:5-616, 2021 - I.F. 3,75

133 – Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers

  • AUTORI: Toss A., Tenedini E., Piombino C., Venturelli M., Marchi I., Gasparini E., Barbieri E. et al.
Abstract: The most common breast cancer (BC) susceptibility genes beyond BRCA1/2 are ATM and CHEK2. For the purpose of exploring the clinicopathologic characteristics of
  • Rivista:
  • Biomedicines 9:3-312, 2021 - I.F. 4,71

132 – The Role of Exosomes in Breast Cancer Diagnosis

  • AUTORI: Piombino C., Mastrolia I., Omarini C., Candini O., Dominici M., Piacentini F., Toss A.
Abstract: The importance of molecular re-characterization of metastatic disease with the purpose of monitoring tumor evolution has been acknowledged in numerous clinical guidelines for
  • Rivista:
  • Diagnostic 11:3-565, 2021 - I.F. 5,25

131 – The Prognostic and Predictive Role of Somatic BRCA Mutations in Ovarian Cancer: Results from a Multicenter Cohort Study

  • AUTORI: Toss A., Piombino C., Tenedini E., Bologna A., Gasparini E., Tarantino V., Filieri ME. et al.
Abstract: Previous research involving epithelial ovarian cancer patients showed that, compared to germline BRCA (gBRCA) mutations, somatic BRCA (sBRCA) mutations present a similar positive
  • Rivista:
  • Journal of Personalized Medicine, 11:4-245, 2021 - I.F. 4,90

130 – Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors?

  • AUTORI: Cortesi L., Domati F., Guida A., Marchi I., Toss A., Barbieri E. et al.
Abstract: The homologous recombination repair (HRR) pathway repairs double-strand DNA breaks, mostly by BRCA1 and BRCA2, although other proteins such as ATM, CHEK2, and
  • Rivista:
  • Cancer Biology and Medicine, 18:2-470:476, 2021 - I.F. 5,43

129 – BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees

  • AUTORI: Cortesi L., Domati F., Guida A., Marchi I., Toss A., Barbieri E., Marcheselli L. et al.
Objective: As prostate cancer (PrC) shows a BRCA mutation rate as high as 30%, it becomes crucial to find the optimal selection criteria for
  • Rivista:
  • Journal of Oncology, 2020 - I.F. 4,37

128 – Secondary Prevention in Hereditary Breast and/or Ovarian Cancer Syndromes Other Than BRCA

  • AUTORI: Piombino C., Cortesi L., Lambertini M., Punie K., Grandi G., Toss A.
BRCA1- and BRCA2-associated hereditary breast and ovarian cancer syndromes are among the best-known and most extensively studied hereditary cancer syndromes. Nevertheless, many patients who
  • Rivista:
  • ESMO Open 6:2, 2021 - I.F. 4,93

127 – Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era

  • AUTORI: Toss A., Isca C., Venturelli M., Nasso C., Ficarra G., Bellelli V., Armocida C. et al.
Introduction: The present analysis aims to evaluate the consequences of a 2-month interruption of mammographic screening on breast cancer (BC) stage at diagnosis and
  • Rivista:
  • British Journal of Haematology 192:6-1011:1014, 2021 - I.F. 5,02

126 – Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma

  • AUTORI: Massaro F., Stepanishyna Y., Manni M., Luminari S., Galimberti S., Marcheselli L., Visco C. et al.
Mantle cell lymphoma is a rare and incurable lymphoproliferative disorder. In the MCL01 trial, patients were treated with the R-HCVAD regimen [rituximab plus HyperCVAD
  • Rivista:
  • Cancers 12:5-1252, 2020 - I.F. 6,12

124 – BRCA Detection Rate in an Italian Cohort of Luminal Early-Onset and Triple-Negative Breast Cancer Patients without Family History: When Biology Overcomes Genealogy

  • AUTORI: Toss A., Molinaro E., Venturelli M., Domati F., Marcheselli L., Piana S. et al.
NCCN Guidelines recommend BRCA genetic testing in individuals with a probability >5% of being a carrier. Nonetheless, the cost-effectiveness of testing individuals with no
  • Rivista:
  • International Journal of Molecular Sciences 19:8-2337, 2018 - I.F. 4,55

121 – The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease

  • AUTORI: Cosenza M., Pozzi S.
Histone deacetylases (HDACs) are master regulators of chromatin remodeling, acting as epigenetic regulators of gene expression. In the last decade, inhibition of HDACs has
  • Rivista:
  • Journal of Clinical Oncology 36:7-689:696, 2018 - I.F. 28,24

120 – Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma

  • AUTORI: Luminari S., Ferrari A., Manni M., Dondi A., Chiarenza A., Merli F. et al.
Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) and R-FM (rituximab
  • Rivista:
  • Cancers 11:2-193:204, 2019 - I.F. 6,12

119 – Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies

  • AUTORI: Toss A., Venturelli M., Molinaro E., Pipitone S., Barbieri E., Marchi I., Tenedini E., Artuso L., Castellano S., Marino M., Tagliafico E., Razzaboni E., De Matteis E., Cascinu S., Cortesi L.
The identification of BRCA mutations plays a crucial role in the management of hereditary cancer prevention and treatment. Nonetheless, BRCA-testing in pancreatic cancer (PC)
  • Rivista:
  • Frontiers in Oncology 8-254, 29 - I.F. 4,41

118 – LonP1 differently modulates mitochondrial function and bioenergetics of primary versus metastatic colon cancer cells

  • AUTORI: Gibellini L., Losi L., De Biasi S., Nasi M., Lo Tartaro D. et al
Mitochondrial Lon protease (LonP1) is a multi-function enzyme that regulates mitochondrial functions in several human malignancies, including colorectal cancer (CRC). The mechanism(s) by which
  • Rivista:
  • British Journal of Haematology 181:6-760:769, 2019 - I.F. 6,99

116 – Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), AS new prognostic model developed by the International T-cell Project Network

  • AUTORI: Federico M., Bellei M., Marcheselli L., Schwartz M., Manni M., Tarantino V. et al
Different models to investigate the prognosis of peripheral T cell lymphoma not otherwise specified (PTCL-NOS) have been developed by means of retrospective analyses. Here
  • Rivista:
  • Oncotarget 8:61-103797:103814, 2017 - I.F. 3,33

114 – Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases

  • AUTORI: Civallero M., Cosenza M., Pozzi S., Sacchi S.
JAK-2 dysregulation plays an important role as an oncogenic driver, and is thus a promising therapeutic target in hematological malignancies. Ruxolitinib is a pyrrolo[2.3-d]pyrimidine
  • Rivista:
  • Oncology 93:6-377:386, 2017 - I.F. 2,93

113 – Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo- Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study

  • AUTORI: Cortesi L., De Matteis E., Toss A., Marchi I., Medici V., Contu G. et al.
Objective: To evaluate the effectiveness of transvaginal ultrasound (TVU) and serum CA-125 measurement in women at different risk of developing ovarian cancer/fallopian tube cancer
  • Rivista:
  • Hematological Oncology 35:4-630:636, 2016 - I.F. 5,27

110 – Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-Cell Project, an international, cooperative study

  • AUTORI: Bellei M., Sabattini E., Pesce EA., Ko YH., Kim WS., Cabreras ME. et al.
Peripheral T-cell lymphomas (PTCLs) comprise a heterogeneous group of neoplasms that are derived from post-thymic lymphoid cells at different stages of differentiation with different
  • Rivista:
  • BioMed Research International 1:12, 2015 - I.F. 3,41

108 – Activity of BKM120 and BEZ235 against lymphoma cells

  • AUTORI: Civallero M., Cosenza M., Pozzi S., Bari A., Ferri P., Sacchi S.
Non-Hodgkin lymphomas encompass a heterogeneous group of cancers, with 85–90% arising from B lymphocytes and the remainder deriving from T lymphocytes or NK lymphocytes.
  • Rivista:
  • Mayo Clinic Proceedings 90:6-756-764, 2015 - I.F. 7,61

107 – Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients

  • AUTORI: Tadmor T., Bari A., Marcheselli L., Sacchi S., Aviv A., Baldini L. et al.
OBJECTIVE: To verify whether absolute monocyte count (AMC) and lymphocyte- monocyte ratio (LMR) at diagnosis are valid prognostic parameters in classical Hodgkin lymphoma (cHL).
  • Rivista:
  • British Journal of Haematololy 169:4-544:551, 2015 - I.F. 6,99

106 – Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi

  • AUTORI: Marcheselli L., Bari A., Anastasia A., Botto B., Puccini B. et al.
Recently, in an attempt to improve the discrimination power of the international prognostic index (IPI), patients with diffuse large B-cell lymphoma were evaluated to
  • Rivista:
  • Annals of Epidemiology 25:8-564:568, 2015 - I.F. 3,79

105 – Cancer incidence, mortality, and survival in Eastern Libya: updated report from the Benghazi Cancer Registry

  • AUTORI: El Mistiri M., Salati M., Marcheselli L., Attia A., Habil S. et al.
Purpose: Despite the increasing burden of cancer occurred over recent years in the African continent, epidemiologic data from Northern Africa area have been so
  • Rivista:
  • International Journal of Cancer 137:6-1417:1426, 2015 - I.F. 7,39

104 – Twenty-years experience with de novo metastatic breast cancer

  • AUTORI: Cortesi L., Toss A., Cirilli C., Marcheselli L., Braghiroli B., Sebastiani F., Federico M.
Although new treatments have been widely studied to improve the survival of patients with metastatic breast cancer (BC), prognosis continues to be poor with
  • Rivista:
  • Hematological Oncology 33:4-166:175, 2015 - I.F. 5,27

103 – The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines

  • AUTORI: Cosenza M., Civallero M., Pozzi S., Marcheselli L., Bari A., Sacchi S.
We analyzed the combination of a proteasome inhibitor (bortezomib) with enzastaurin (PKC/AKT-inhibitor) or lenalidomide (immunomodulatory agent) for the inhibition of proliferation and induction of
  • Rivista:
  • Britisch JOurnal of Haematology 165:6-892, 2014 - I.F. 6,99

102 – Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma-response to Murphy et al

  • AUTORI: Pozzi S., Bari A., Sacchi S.
The study by Murphy et al supports the observation made by several groups regarding the benefit of the novel agents in both young and
  • Rivista:
  • Expert Opinion Investig Drugs 23:5-711:718, 2014 - I.F. 6,20

101 – The Potential Of Pralatrexate As A Treatment Of Peripheral T-Cell Lymphoma

  • AUTORI: Dondi A., Bari A., Pozzi S., Ferri P., Sacchi S.
Introduction: Peripheral T-cell lymphomas (PTCLs) are a group of rare malignancies originating from clonal proliferation of mature, post-thymic T cells that represent 10 —
  • Rivista:
  • Journal Clinical of Oncology 32:12-1188:1194, 2014 - I.F. 44,54

100 – Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial

  • AUTORI: Raemaekers JM., André MP., Federico M., Girinsky T., Oumedaly R., Brusamolino E., Brice P. et al.
Purpose Combined-modality treatment is standard treatment for patients with clinical stage I/II Hodgkin lymphoma (HL). We hypothesized that an early positron emission tomography (PET)
  • Rivista:
  • Annals of Oncology 25-442:447, 2014 - I.F. 32,97

98 – The prognostic role of post-induction FDG-PET in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)

  • AUTORI: Luminari S., Biasoli I., Versari A., Rattotti S., Bottelli C., Rusconi C., Merli F., Spina M., Ferreri A.J.M., Zinzani P.L. et al.
Background: [ 18F]fluorodeoxyglucose-positron emission tomography (PET) is emerging as a strong diagnostic and prognostic tool in follicular lymphoma (FL) patients. Patients and methods: In
  • Rivista:
  • Haematologica 99:1-125:130, 2014 - I.F. 9,54

97 – Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era

  • AUTORI: Tadmor T., Bari A., Sacchi S., Marcheselli L., Liardo EV., Avivi I., Beniamini N. et al.
In this study we assessed the prognostic significance of absolute monocyte count and elected the best cut-off value at diagnosis, in a large cohort
  • Rivista:
  • Annals of Oncology 25-57:63, 2014 - I.F. 32,97

96 – A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive Italian women

  • AUTORI: Cortesi L., Razzaboni E., Toss A., De Matteis E., Marchi I., Medici V., Tazzioli G., Andreotti A., De Santis G., Pignatti M., Federico M.
Background: Risk-reducing mastectomy (RRM) decreases breast cancer (BC) risk in BRCA1/2 mutation carriers by up to 95%, but the Italian attitude towards this procedure
  • Rivista:
  • British Journal of Haematology 163:1-40:46, 2013 - I.F. 6,99

93 – Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis

  • AUTORI: Pozzi S., Marcheselli L., Bari A., Liardo EV., Marcheselli R. et al.
Novel treatments for multiple myeloma (MM) have shown promising results in clinical trials, but the advantage in unselected patients is still unclear. In order
  • Rivista:
  • Journal Clinical of Oncology 31:27-3351:3359, 2013 - I.F. 44,54

92 – Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi

  • AUTORI: Vitolo U., Ladetto M., Boccomini C., Baldini L., De Angelis F., Bari A. et al.
Purpose To evaluate the efficacy of rituximab maintenance in 60- to 75-year-old patients with advanced follicular lymphoma responding to brief first-line chemoimmunotherapy followed by
  • Rivista:
  • European Journal of Haematology 90:4-345:348 2013 - I.F. 2,99

90 – Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia

  • AUTORI: Voso MT., Breccia M., Lunghi M., Poloni A., Niscola P., Bari A. et al.
In patients with myelodysplastic syndromes (MDS), the likelihood of having a sustained response to azacitidine is increased by maximizing treatment duration. This is important
  • Rivista:
  • Annals of Oncology 24:8-2108-2112, 2013 - I.F. 32,97

88 – The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from FOLL05 randomized trial of the Fondazione Italiana Linfomi

  • AUTORI: Luminari S., Biasoli I., Arcaini L., Versari A., Rusconi C., Merli F., Spina M., Ferreri AJM., Zinzani PL., Gallamini A., Mastronardi S., Boccomini C., Gaidano G., D’Arco A.M., Di Raimondo F., Carella AM., Santoro A., Musto P., Federico M.
Background: The role of [¹⁸F] fluorodeoxyglucose (FDG)-positron emission tomography (PET) in follicular lymphoma (FL) staging is not yet determined. Patients and methods: The aim

RICERCA SUL CANCRO

PUBBLICAZIONI SCIENTIFICHE

Tutti i nostri articoli pubblicati sulle riviste scientifiche
VAI

PROGETTI DI RICERCA

I progetti di ricerca che abbiamo sostenuto
VAI

BORSE DI STUDIO E STAGE ALL'ESTERO

Borse di studio e stage all'estero per ricercatori finanziati dall'Associazione
VAI

PREMI DI STUDIO

Premi di studio per la ricerca contro i tumori
VAI

PREMIO "PIER CAMILLO BECCARIA"

Conferito ogni anno ad un illustre studioso che si è distinto nella lotta contro i tumori
VAI

ASSOCIAZIONE ANGELA SERRA PER LA RICERCA SUL CANCRO ODV – C.F. 94012300367 – Email: serra@unimore.it
Policy Policy – Cookie Policy